354 related articles for article (PubMed ID: 27157799)
1. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
[TBL] [Abstract][Full Text] [Related]
4. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
[TBL] [Abstract][Full Text] [Related]
5. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
[TBL] [Abstract][Full Text] [Related]
6. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole for the treatment of schizophrenia.
Yee A
Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
[TBL] [Abstract][Full Text] [Related]
10. Brexpiprazole for the treatment of schizophrenia.
Hsu WY; Lane HY; Lin CH
Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Kishi T; Ikuta T; Matsuda Y; Sakuma K; Iwata N
Psychopharmacology (Berl); 2020 May; 237(5):1459-1470. PubMed ID: 32002559
[TBL] [Abstract][Full Text] [Related]
12. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
Newcomer JW; Eriksson H; Zhang P; Weiller E; Weiss C
Curr Med Res Opin; 2018 Dec; 34(12):2197-2205. PubMed ID: 29985680
[TBL] [Abstract][Full Text] [Related]
13. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Antoun Reyad A; Girgis E; Mishriky R
Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole: A Review in Schizophrenia.
Frampton JE
Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
McIntyre RS; Weiller E; Zhang P; Weiss C
J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
[TBL] [Abstract][Full Text] [Related]
19. Brexpiprazole.
Markovic M; Gallipani A; Patel KH; Maroney M
Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
[TBL] [Abstract][Full Text] [Related]
20. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
Ekinci A; Ekinci O
Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
